HAEMONETICS CORP/MASS (HAE) Stock Price, Quote, News and Overview
NYSE:HAE - New York Stock Exchange, Inc. - US4050241003 - Common Stock - Currency: USD
HAE Quote, Performance and Key Statistics
63.02
-0.43 (-0.68%)
The current stock price of HAE is 63.02 USD. In the past month the price decreased by -13.51%. In the past year, price decreased by -14.27%.
HAE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.9 | 45.13B | ||
| COO | COOPER COS INC/THE | 23.91 | 17.66B | ||
| ALGN | ALIGN TECHNOLOGY INC | 20.39 | 14.22B | ||
| SOLV | SOLVENTUM CORP | 17.55 | 12.61B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 30.7 | 6.01B | ||
| BLCO | BAUSCH + LOMB CORP | 25.4 | 5.55B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.27 | 5.44B | ||
| ICUI | ICU MEDICAL INC | 27.69 | 3.85B | ||
| XRAY | DENTSPLY SIRONA INC | 10.14 | 3.73B | ||
| NEOG | NEOGEN CORP | 25.1 | 2.18B | ||
| UFPT | UFP TECHNOLOGIES INC | 36.31 | 1.95B | ||
| RXST | RXSIGHT INC | N/A | 1.19B |
Related stock screener links
About HAE
Company Profile
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,657 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.
Company Info
HAEMONETICS CORP/MASS
125 Summer Street
Boston MASSACHUSETTS 02110 US
CEO: Christopher A. Simon
Employees: 3657
Company Website: https://www.haemonetics.com
Investor Relations: https://haemonetics.gcs-web.com
Phone: 17818487100
HAEMONETICS CORP/MASS / HAE FAQ
What is the stock price of HAEMONETICS CORP/MASS today?
The current stock price of HAE is 63.02 USD. The price decreased by -0.68% in the last trading session.
What is the ticker symbol for HAEMONETICS CORP/MASS stock?
The exchange symbol of HAEMONETICS CORP/MASS is HAE and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is HAE stock listed?
HAE stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for HAEMONETICS CORP/MASS stock?
14 analysts have analysed HAE and the average price target is 113.02 USD. This implies a price increase of 79.33% is expected in the next year compared to the current price of 63.02. Check the HAEMONETICS CORP/MASS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HAEMONETICS CORP/MASS worth?
HAEMONETICS CORP/MASS (HAE) has a market capitalization of 3.17B USD. This makes HAE a Mid Cap stock.
How many employees does HAEMONETICS CORP/MASS have?
HAEMONETICS CORP/MASS (HAE) currently has 3657 employees.
What are the support and resistance levels for HAEMONETICS CORP/MASS (HAE) stock?
HAEMONETICS CORP/MASS (HAE) has a resistance level at 64.1. Check the full technical report for a detailed analysis of HAE support and resistance levels.
Is HAEMONETICS CORP/MASS (HAE) expected to grow?
The Revenue of HAEMONETICS CORP/MASS (HAE) is expected to grow by 7.65% in the next year. Check the estimates tab for more information on the HAE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HAEMONETICS CORP/MASS (HAE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HAE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HAE, evaluating the profitability, health, valuation and growth aspects
- HAEMONETICS CORP/MASS (HAE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HAEMONETICS CORP/MASS (HAE) Sales and EPS estimates to see what analysts future expectations are.
- HAEMONETICS CORP/MASS (HAE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HAEMONETICS CORP/MASS (HAE) Insider and Institutional Ownership to learn about the owners and their transactions.
- HAEMONETICS CORP/MASS (HAE) Stock Chart to make your own analysis
- HAEMONETICS CORP/MASS (HAE) Latest news and press-releases to stay up to date.
Does HAEMONETICS CORP/MASS (HAE) stock pay dividends?
HAE does not pay a dividend.
When does HAEMONETICS CORP/MASS (HAE) report earnings?
HAEMONETICS CORP/MASS (HAE) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of HAEMONETICS CORP/MASS (HAE)?
The PE ratio for HAEMONETICS CORP/MASS (HAE) is 14.9. This is based on the reported non-GAAP earnings per share of 4.23 and the current share price of 63.02 USD. Check the full fundamental report for a full analysis of the valuation metrics for HAE.
What is the Short Interest ratio of HAEMONETICS CORP/MASS (HAE) stock?
The outstanding short interest for HAEMONETICS CORP/MASS (HAE) is 10.53% of its float. Check the ownership tab for more information on the HAE short interest.
HAE Technical Analysis
HAE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to HAE. HAE scores excellent on profitability, but there are some minor concerns on its financial health.
HAE Financial Highlights
Over the last trailing twelve months HAE reported a non-GAAP Earnings per Share(EPS) of 4.23. The EPS increased by 9.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.1% | ||
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| Debt/Equity | 1.39 |
HAE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to HAE. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 15.36% and a revenue growth 7.65% for HAE